furosemide has been researched along with Cardiac Remodeling, Ventricular in 14 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis." | 7.85 | Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017) |
| "CHF was characterized by left ventricular remodeling and impaired systolic and diastolic function." | 5.35 | Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. ( Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2008) |
| " The most widely used diuretic, furosemide, has a stormy pharmacokinetics and pharmacodynamics, and is associated with a high risk of mortality and hospitalization for worsening heart failure." | 5.24 | The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial. ( Bakuła, E; Balsam, P; Cacko, A; Filipiak, KJ; Fojt, A; Grabowski, M; Główczyńska, R; Huczek, Z; Kowalik, R; Markulis, M; Opolski, G; Ozierański, K; Peller, M; Sieradzki, B; Tymińska, A, 2017) |
| "To determine the effect of torasemide, a loop diuretic with antialdosteronergic properties, compared with furosemide on cardiac sympathetic nerve activity in patients with congestive heart failure (CHF)." | 5.12 | Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. ( Hatori, T; Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T, 2006) |
| "Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis." | 3.85 | Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017) |
| "We compared therapeutic effects of furosemide, a short-acting loop diuretic, and azosemide, a long-acting one, in hypertensive heart failure rats to test the hypothesis that long-acting diuretics are superior to short-acting types in heart failure." | 3.73 | Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishio, M; Ohtani, T; Sakata, Y; Yamamoto, K; Yoshida, J, 2005) |
| "Reverse ventricular remodeling obtained with carvedilol, ramipril/candesartan, and spironolacton is associated with decreases in left ventricular end-diastolic volume, left ventricular end-systolic volume, tenascin-C levels, and NT-proBNP levels." | 2.78 | Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy. ( Akpek, M; Kaya, EG; Kaya, MG; Lam, YY; Sarli, B; Topsakal, R, 2013) |
| "While rare, improvement in mitral regurgitation severity may occur without surgical intervention, allowing for reverse left-sided cardiac remodeling and discontinuation of furosemide." | 1.91 | Resolution of congestive heart failure and reverse remodeling in two Chihuahuas with flail mitral valve leaflets. ( Wesselowski, S, 2023) |
| "Spironolactone treatment demonstrated significant attenuation of cardiac fibrosis and apoptosis in left ventricular tissue compared to furosemide." | 1.72 | Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction. ( Chang, WT; Chen, CY; Chen, ZC; Lin, YW; Liu, PY; Luo, CY; Shih, JY; Wu, CC, 2022) |
| "CHF was characterized by left ventricular remodeling and impaired systolic and diastolic function." | 1.35 | Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. ( Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2008) |
| "Heart failure is often treated with ACE inhibitors and diuretics although diuretic treatment could activate the renin-angiotensin system (RAS)." | 1.32 | Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats. ( Böhm, M; Itter, G; Jockenhövel, F; Kouchi, I; Linz, W; Seeland, U; Zolk, O, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WT | 1 |
| Lin, YW | 1 |
| Chen, CY | 1 |
| Chen, ZC | 1 |
| Shih, JY | 1 |
| Wu, CC | 1 |
| Luo, CY | 1 |
| Liu, PY | 1 |
| Wesselowski, S | 1 |
| Sarli, B | 1 |
| Topsakal, R | 1 |
| Kaya, EG | 1 |
| Akpek, M | 1 |
| Lam, YY | 1 |
| Kaya, MG | 1 |
| Yamazaki, T | 1 |
| Nakamura, Y | 1 |
| Shiota, M | 1 |
| Osada-Oka, M | 1 |
| Fujiki, H | 1 |
| Hanatani, A | 1 |
| Shimada, K | 1 |
| Miura, K | 1 |
| Yoshiyama, M | 1 |
| Iwao, H | 1 |
| Izumi, Y | 1 |
| Luo, J | 1 |
| Chen, X | 1 |
| Luo, C | 1 |
| Lu, G | 1 |
| Peng, L | 1 |
| Gao, X | 1 |
| Zuo, Z | 1 |
| Balsam, P | 1 |
| Ozierański, K | 1 |
| Tymińska, A | 1 |
| Główczyńska, R | 1 |
| Peller, M | 1 |
| Fojt, A | 1 |
| Cacko, A | 1 |
| Sieradzki, B | 1 |
| Bakuła, E | 1 |
| Markulis, M | 1 |
| Kowalik, R | 1 |
| Huczek, Z | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Grabowski, M | 1 |
| Tanaka, H | 1 |
| Watanabe, K | 2 |
| Harima, M | 1 |
| Thanikachalam, PV | 1 |
| Yamaguchi, K | 2 |
| Tachikawa, H | 1 |
| Kodama, M | 2 |
| Aizawa, Y | 2 |
| Seeland, U | 2 |
| Kouchi, I | 2 |
| Zolk, O | 2 |
| Jockenhövel, F | 1 |
| Itter, G | 2 |
| Linz, W | 2 |
| Böhm, M | 2 |
| Yoshida, J | 1 |
| Yamamoto, K | 1 |
| Mano, T | 1 |
| Sakata, Y | 1 |
| Nishio, M | 1 |
| Ohtani, T | 1 |
| Hori, M | 1 |
| Miwa, T | 1 |
| Masuyama, T | 1 |
| Kasama, S | 1 |
| Toyama, T | 1 |
| Hatori, T | 1 |
| Sumino, H | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Ichikawa, S | 1 |
| Suzuki, T | 1 |
| Kurabayashi, M | 1 |
| Cohen, N | 1 |
| Golik, A | 1 |
| Badenhorst, D | 1 |
| Norton, GR | 1 |
| Sliwa, K | 1 |
| Brooksbank, R | 1 |
| Essop, R | 1 |
| Sareli, P | 1 |
| Woodiwiss, AJ | 1 |
| Veeraveedu, PT | 1 |
| Ma, M | 1 |
| Palaniyandi, SS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial[NCT01942109] | Phase 4 | 100 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| Japanese Multicenter Evaluation of Long- Versus Short-acting Diuretics in Congestive Heart Failure[NCT00355667] | Phase 4 | 320 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for furosemide and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Zinc balance and medications commonly used in the management of heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Furosemi | 2006 |
4 trials available for furosemide and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Carbazoles; Cardiomyopathy, Dilat | 2013 |
The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.
Topics: Biomarkers; Chronic Disease; Clinical Protocols; Echocardiography; Electrocardiography, Ambulatory; | 2017 |
Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure.
Topics: Aged; Autonomic Nervous System Diseases; Diuretics; Female; Furosemide; Heart Failure; Humans; Male; | 2006 |
Impact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Cardiotonic Agents; Cardiovascula | 2007 |
9 other studies available for furosemide and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction.
Topics: Animals; Fibrosis; Furosemide; Heart Failure; Mineralocorticoid Receptor Antagonists; Mitral Valve I | 2022 |
Resolution of congestive heart failure and reverse remodeling in two Chihuahuas with flail mitral valve leaflets.
Topics: Animals; Dog Diseases; Dogs; Furosemide; Heart Failure; Heart Valve Diseases; Male; Mitral Valve; Mi | 2023 |
Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.
Topics: Acute-Phase Reaction; Animals; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibr | 2013 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel | 2017 |
[Effects of various diuretics on cardiac function in rats with heart failure].
Topics: Animals; Cytochrome P-450 CYP11B2; Disease Models, Animal; Diuretics; Furosemide; Heart Failure; Hem | 2009 |
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Chronic Disease; Disease Models, Animal; Diuretic | 2003 |
Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats.
Topics: Animals; Echocardiography; Furosemide; Heart Failure; Interleukin-1; Norepinephrine; Rats; Rats, Inb | 2005 |
Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; | 2008 |
Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Extracellular Matrix; Extracellular Ma | 2002 |